DIS3L2: A Potential Drug Target and Biomarker for Disrupting Mitotic Control

Target Name: DIS3L2

NCBI ID: G129563

DIS3L2

DIS3L2: A Potential Drug Target and Biomarker for Disrupting Mitotic Control

Introduction

Mitosis is a critical process in cell division that leads to the development and progression of cancer. Disrupting the control of mitosis is a potential strategy for targeting cancer cells. One gene that has been identified as a potential drug target for mitosis is DIS3L2, also known as DIS3L2-like 2. In this article, we will explore the biology of DIS3L2 and its potential as a drug target and biomarker for cancer.

Structure and Function

DIS3L2 is a member of the DIS3 gene family, which includes several related genes that are involved in the regulation of mitosis. The DIS3 gene family is characterized by the presence of a conserved domain that includes a leucine-rich repeat and a unique N-terminal translocation step. This conserved domain is also present in several non-coding RNA molecules, including DIS3L2.

DIS3L2 is expressed in a variety of tissues and cells, including fetal liver, brain, and testes. It is highly expressed in cancer cells, and has been used as a biomarker for several types of cancer, including pancreatic, colorectal, and ovarian cancers. In addition, DIS3L2 has also been shown to be expressed in normal tissues, which suggests that it may have a non-cancerous role in the body.

DIS3L2 functions as a negative regulator of mitosis by preventing the metaphase transition from G1 to G2. This means that when a cell is in G1 phase, DIS3L2 is active and prevents the cell from entering G2 phase, where cell division would occur. This regulation of Mitosis is critical for the proper development and progression of cancer cells, as it allows cells to continue to grow and divide without undergoing the potentially dangerous process of cell division.

DIS3L2 has been shown to interact with several other genes that are involved in the regulation of mitosis. For example, it has been shown to physically interact with the protein kinase PDK4, which is involved in the regulation of mitosis. This interaction may regulate the activity of PDK4 and disrupt its role in controlling the metaphase transition.

DIS3L2 has also been shown to interact with the protein tyrosine kinase (TK)2, which is involved in the regulation of cell growth and differentiation. This interaction may regulate the activity of TK2 and disrupt its role in controlling cell growth.

DIS3L2 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as the angiogenesis that allows cancer cells to access oxygen and nutrients.

Drug Target Potential

DIS3L2 is a potential drug target for cancer because of its role in regulating mitosis and its involvement in several processes that are important for cancer progression. Disrupting the control of mitosis by disrupting the activity of DIS3L2 may be an effective way to target cancer cells.

One approach to targeting DIS3L2 is to use small molecules that can inhibit its activity as a negative regulator of mitosis. This could be done by binding to specific sites on DIS3L2 that are involved in its regulation of mitosis.

Another approach to targeting DIS3L2 is to use drugs that can disrupt its interactions with other genes involved in the regulation of mitosis. This could be done by inhibiting the activity of DIS3L2 in

Protein Name: DIS3 Like 3'-5' Exoribonuclease 2

Functions: 3'-5'-exoribonuclease that specifically recognizes RNAs polyuridylated at their 3' end and mediates their degradation. Component of an exosome-independent RNA degradation pathway that mediates degradation of both mRNAs and miRNAs that have been polyuridylated by a terminal uridylyltransferase, such as ZCCHC11/TUT4. Mediates degradation of cytoplasmic mRNAs that have been deadenylated and subsequently uridylated at their 3'. Mediates degradation of uridylated pre-let-7 miRNAs, contributing to the maintenance of embryonic stem (ES) cells. Essential for correct mitosis, and negatively regulates cell proliferation

The "DIS3L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIS3L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets